
X

X

X



USSN 09/391,783 Baldwin *et al.* Page -2-

R¹ is OH, O(CH₂)₁₋₂OH, OCH₂CO₂H, CO₂H, O-Z-C(O)NHCHR/ 8 (CH₂)₀₋₅R¹⁷ O-Z-C(O)NH(CH₂)₁₋₆R¹⁷ or [OCH₂-4-Phe-C(O)NHCHR₁₆(CH₂)₀₋₅R¹⁷] OCH₂-4-Phe-C(O)NH(CH₂)₁₋₆R¹⁷;

 \mathbb{R}^2 is H or lower alkyl;

R³ is H, alkyl, aryl, or arylalkyl;

R' and R' are each independently H, lower alkyl, or substituted lower alkyl where the substituents are 1-3 alkoxy, aryl, substituted aryl, carboalkoxy, carboxamido.

R¹ and R³ taken together are $-(CH_2)_n$ -, $-(CH_2)_2$ -O- $(CH_2)_2$ -, $-CH_2$ -O- $(CH_2)_3$ -, $-(CH_2)_2$ -NR⁸- $(CH_2)_2$ -, $-CH_2$ -NR⁸- $(CH_2)_m$ -, $-(CH_2)_2$ XH(NHR⁸) $(CH_2)_2$ - $-(CH_2)_2$ CH(NHR⁸) $(CH_2)_2$ -, $-(CH_2)_2$ -S(O)₀₋₂- $(CH_2)_2$ -, or $-(CH_2)_2$ CH(N-loweralkyl) $-(CH_2)_2$ CHCH₂-;

one of R^6 and R^7 is H and the other is H, OH, $\sqrt{r} N(CH_2)_{1-6}R^{14}R^{15}$; or

 R^6 and R^7 taken together are R^6 , R^6 , R^7 , R^8 , R^8 , R^8 , with the proviso that when R^1 is -OH and R^2 is -H, R^6 and R^7 are not -H and -OH or when taken together are not

R* is H, COOR⁹, CONHR¹⁰, CSNHR¹¹, COR¹², SO₂R¹³, lower alkyl, aryl lower alkyl, heteroaryl, or heteroaryl lower alkyl, wherein aryl is optionally substituted with 1-3 substituents selected from lower alkyl, lower alkoxy, halo, CN, NH₂, COOH, CONH₂, carboalkoxy, and mono- or di-lower alkylamino and wherein heteroaryl is a mono- or

NAUSPIRSMEARPACCAPHRAMONAMERRO June 9, 2000


X

۶



USSN 09/391,783 Baldwin *et al.* Page -3-

- bicyclic heteroaromatic ring system of 5 to 10 members including 1 to 3 heteroatoms selected from O, N, and S and 0-3 substituents selected from halo, amino, cyano, lower alkyl, carboalkoxy, CONH₂, and S-lower alkyl;
- R° is lower alkyl, aryl lower alkyl, heteroaryl, aryl substituted by 1-3 substituents selected from alkyl, alkenyl, alkoxy, methylene dioxy, and halo, or a 5- to 6-membered heterocyclic ring wherein the hetero atom is O or N, wherein heteroaryl is a heteroaromatic ring of 5 to 6 members including 1 to 2 heteroatoms selected from O, N, and S and 0-2 substituents selected from lower alkyl, dialkylamino, lower alkoxy, and halo,
- R¹⁰ and R¹¹ are each independently lower alkyl, aryl lower alkyl, or aryl substituted by 1-3 substituents selected from lower alkyl, halo, alkoxy and haloalkyl;
- R¹² is lower alkyl, aryl, heteroaryl, aryl lower alkyl, heteroaryl lower alkyl, a 5- or 6-membered heterocyclic ring containing 1-2 heteroatoms selected from O, S, and N, a 5- or 6-membered heterocyclic ring containing 1-2 heteroatoms selected from O, S and lower alkyl, or aryl substituted with 1-3 substituents selected from lower alkyl, alkoxy, halo, sulfamoyl, lower alkyl sulfamoyl, gyano, and phenyl;
- R¹¹ is lower alkyl, aryl, or aryl substituted with 1-3 substituents selected from lower alkyl, alkoxy, halo, CN, and haloalkyl;
- R¹⁴ is H; [alkyl]; alkyl substituted by 1-3/alkoxy, [S-, loweralkyl] <u>S-loweralkyl</u>, sulfamoyl, halo, alkylsulphonamido, or arylsulphonamido; alkenyl; alkynyl; aryl; substituted aryl; heteroaryl; substituted heteroaryl; heterocycloalkyl; -CH₂NR¹⁶C(O)R¹⁶;-C(O)NR¹⁶R¹⁶; -CH₂OC(O)R¹⁶; or -CH₂SC(O)R¹⁶;
- R^{15} is H, alkyl, -C(O)X, -C(S)X, or $/C(NCN)NR^3R^3$;
- R¹⁶ is lower alkyl, substituted lower alkyl, aryl, or substituted aryl;
- R¹⁷ is H; [alkyl;] alkyl substituted by 1-3 alkoxy, [S-, loweralkyl] <u>S-loweralkyl</u>, sulfamoyl, halo, alkylsulphonamido, or arylsulphonamido; alkenyl; alkynyl; aryl; substituted aryl;



USSN 09/391,783 Baldwin *et al.* Page -4-

heteroaryl; substituted heteroaryl; heterocycloalkyl; | heterocycloalkyl; diphenylmethyl; | $-CH_2NR^{16}C(O)R^{16}$; $-C(O)NR^{16}R^{16}$; $-CH_2OC(O)R^{16}$; or $-CH_2SC(O)R^{16}$;

[R^{18} is H or $-(CH_2)_{0.5}R^{17}$];

X is alkyl, aryl, arylalkyl, O-loweralkyl, or -NR³R³;

Z is -(CH₂)₁₋₆-, optionally substituted with 1-3 lower alkyl; -CHR²-; -Phe-CH₂-, where Phe is optionally mono-substituted with halogen, lower alkyl, or alkoxy; or heteroarylene-(CH₂)-;

m is 2 or 3;

n is 4-9;

or a pharmaceutically acceptable salt thereof.

7. (once amended) A compound of claim 4 wherein:

R¹ is OH, OCH₂C(O)NH(CH₂)₁₋₆R¹⁷, or OCH₂-4-Phe-C(O)NH(CH₂)₁₋₆R¹⁷;

R² is H or lower alkyl;

 R^{1} and R^{5} are each lower alkyl | or $-(CH_{2})_{1-4} - N$ | ; or

 $R^4 \text{ and } R^5 \text{ taken together are -}(CH_2)_{5^-}, -(CH_2)_{2^-}O^-(CH_2)_{2^-}, \\ -(CH_2)_{2^-}N^2R^8 - (CH_2)_{2^-}, -(CH_2)_{2^-}CH(NHR^8)(CH_2)_{2^-}, -(CH_2)_{2^-}S^-(CH_2)_{2^-}, \\ \text{or } CH_2CH(NCH_3)(CH_2)_2CHCH_{2^-};$


 R^6/R^7 are H/OH; -O, or $-S(CH_2)_2$ \$-;

is H, COOR⁹, CONHR¹⁰/CSNHR¹¹, COR¹², SO₂R¹³, lower alkyl, aryl lower alkyl, heteroaryl wherein the ring members include 1 to 3 N atoms and the substituents are halo or amino, heteroaryl lower alkyl wherein heteroaryl is 6-membered and the heteroatoms are N, or aryl lower alkyl substituted with 1 substituent selected from lower alkyl, alkoxy, and halo;

NAUSTERSASTAFFACCAPTERMADONADONH PR

X

X



USSN 09/391,783 Baldwin *et al.* Page -5-

R° is lower alkyl, aryl lower alkyl, aryl, tetrahydrofuranyl, tetrahydropyranyl, or aryl substituted by 1 to 2 substituents selected from lower alkyl, alkenyl, alkoxy, methylene dioxy, and halo;

 R^{10} and R^{11} are each independently aryl, aryl lower alkyl, or aryl substituted by 1 substituent selected from lower alkyl, halo, alkoxy, trifluoromethyl, and pentafluoroethyl;

R¹² is lower alkyl, aryl lower alkyl, heteroaryl lower alkyl wherein the heteroatoms are N, a 5- or 6-membered heterocyclic ring containing 1-2 heteroatoms selected from S and N lower alkyl, or aryl substituted with 1 substituent selected from lower alkyl, alkoxy, halo, sulfamoyl, cyano, or phenyl;

R¹³ is lower alkyl, aryl, or aryl substituted with I substituent selected from lower alkyl, alkoxy, and halo;

or a pharmaceutically acceptable salt thereof.

10. (once amended) A compound of claim I of the formula:


$$R^{1}$$
 R^{2}
 R^{5}
 R^{5}
 R^{5}
 R^{5}

wherein:

R¹ is $[6-\text{or }7-\text{OCH}_2\text{C}(O)\text{NHCHR}^{18}(\text{CH}_2)_{0-5}\text{R}^{17}]$, $6-\text{or }7-\text{OCH}_2-4-\text{Phe-C}(O)\text{NHCHR}_{18}(\text{CH}_2)_{0-5}\text{R}^{17}]$ $\frac{6-\text{ or }7-\text{OCH}_2\text{C}(O)\text{NH}(\text{CH}_2)_{1-6}\text{R}^{17}\text{ or }6-\text{ or }7-\text{OCH}_2-4-\text{Phe-C}(O)\text{NH}(\text{CH}_2)_{1-6}\text{R}^{17}}{\text{when }R_2 \text{ is }H,}$

R¹ is $[7\text{-OCH}_2\text{C}(O)\text{NHCHR}^{18}(\text{CH}_2)_{0.5}\text{R}^{17}, \text{ or } 7\text{-OCH}_2\text{-4-Phe-C}(O)\text{NHCHR}_{18}(\text{CH}_2)_{0.5}\text{R}^{17}]$ $\frac{7\text{-OCH}_2\text{C}(O)\text{NH}(\text{CH}_2)_{1.6}\text{R}^{17} \text{ or } 7\text{-OCH}_2\text{-4-Phe-C}(O)\text{NH}(\text{CH}_2)_{1.6}\text{R}^{17}}{\text{when } \text{R}^2 \text{ is } \text{CH}_3;}$

Not ISBRS/STAFF/CO/PHRA/NOOB/ODB/FPR2 Jone 9, 2,406



USSN 09/391,783 Baldwin *et al.* Page -6-

 $R^4 \text{ and } R^5 \text{ are each methyl; or } R^4 \text{ and } R^5 \text{ taken together are -}(CH_2)_5\text{--}, -(CH_2)_2\text{--}O\text{-}(CH_2)_2\text{--}, \\ -(CH_2)_2\text{--}NR^8\text{--}(CH_2)_2\text{--}, -(CH_2)_2\text{--}CH(NHR^8)(CH_2)_2\text{--}, -(CH_2)_2\text{--}S\text{--}(CH_2)_2\text{--}, or \\ -CH_2CH(NCH_3)(CH_2)_2CHCH_2\text{--}; or } R^4 \text{ is methyl and } R^5 \text{ is -}CH_2OCH_3 \text{ or -}(CH_2)_3N(Et)_2, \\ -(CH_2)_2CH(NCH_3)(CH_2)_2CHCH_2\text{--}; or } R^4 \text{ is methyl and } R^5 \text{ is -}CH_2OCH_3 \text{ or -}(CH_2)_3N(Et)_2, \\ -(CH_2)_2CH(NCH_3)(CH_2)_2CHCH_2\text{--}; or } R^4 \text{ is methyl and } R^5 \text{ is -}CH_2OCH_3 \text{ or -}(CH_2)_3N(Et)_2, \\ -(CH_2)_2CH(NCH_3)(CH_2)_2CHCH_2\text{--}; or } R^4 \text{ is methyl and } R^5 \text{ is -}CH_2OCH_3 \text{ or -}(CH_2)_3N(Et)_2, \\ -(CH_2)_2CH(NCH_3)(CH_2)_2CHCH_2\text{--}; or } R^4 \text{ is methyl and } R^5 \text{ is -}CH_2OCH_3 \text{ or -}(CH_2)_3N(Et)_2, \\ -(CH_2)_2CH(NCH_3)(CH_2)_2CHCH_2\text{--}; or } R^4 \text{ is methyl and } R^5 \text{ is -}(CH_2)_3N(Et)_2, \\ -(CH_2)_3N(Et)_2CHCH_2\text{--}; or } R^4 \text{ is methyl and } R^5 \text{ is -}(CH_2)_3N(Et)_2, \\ -(CH_2)_3N(Et)_2CHCH_2\text{--}; or } R^4 \text{ is methyl and } R^5 \text{ is -}(CH_2)_3N(Et)_2, \\ -(CH_2)_3N(Et)_2CHCH_2\text{--}; or } R^4 \text{ is methyl and } R^5 \text{ is -}(CH_2)_3N(Et)_2, \\ -(CH_2)_3N(Et)_2CHCH_2\text{--}; or } R^4 \text{ is methyl and } R^5 \text{ is -}(CH_2)_3N(Et)_2, \\ -(CH_2)_3N(Et)_2CHCH_2CH$

one of R⁶ and R⁷ is H and the other is OH; or R⁶ and R⁷ taken together are =O or -S(CH₂)₂S-; or one of R⁶ and R⁷ is H and the other is NAB, where A is methyl, 2-methoxyethyl, 2-phenylethyl, 4-methoxybenzyl, 2-tetrahydro-furanylmethyl, 2-(3,4-dimethoxyphenyl)ethyl, or 2,2-diphenylethyl and

B is

H
$$-SO_2CH_3$$
 \nearrow NH NCN NCN NH_2 \nearrow NHCH $_3$ NHCH


R⁸ is II, CONHCH₃, SO₂Phe, (CH₂)₃CH₃, CO(CH₂)₂CH₃, benzyl, C(O)-(4-Phe)-SO₂NH₂, or $\stackrel{N=}{\longrightarrow}$

 $(CH_2)_{1-6}R^{14}$ is methyl, n-butyl, 3-methoxy-n-propyl, CH_2 -c-propyl,or - $(CH_2)_{1-3}$ -phenyl, and $(CH_2)_{1-6}R^{17}$ is methyl, 2-methoxyethyl, 2-phenylethyl, 4-methoxybenzyl,

methyl-2-tetrahydrofuranyl, 2-(3,4-dimethoxyphenyl)ethyl, or 2,2-diphenylethyl; or a pharmaceutically acceptable salt thereof.

Х

χ



USSN 09/391,783 Baldwin *et al.* Page -7-

11. A compound of claim 4 of the formula IIb, IId, or IId:

R¹ is 6- or 7-OH, [6- or 7-OCH₂C(O)NHCHR¹⁸(CH₂)_{0.5}R¹⁷, or 6- or 7-OCH₂-4-Phe-C(O)NHCHR¹⁸(CH₂)_{0.5}R¹⁷] 6- or 7-OCH₃-4-Phe-C(O)NH(CH₂)_{1.6}R¹⁷;

 R^2 is H or CH_1 ,

wherein:

R* is -CO-Phe-p-SO₂NH₂; and

 R^6 and R^7 together are =0 or -SCH₂CH₂S-

Claim 14, delete first table entry wherein:

 R^1 is R^2 is R^4/R^5 is R^6 is R^7 is R^8 is

6-OH	Н	$-(CH_2)_2NR^*(CH_2)_2$	ОН	H	-CONH-Ph-4-CF ₁